Dear Editor, In the spring of 2005, a female patient aged 67 years at that time was referred to our service because of progressive haemoglobin decline. There was no history of bleeding. In 1997, in an external institution, bone marrow aspiration and cytogenetic analysis yielded the diagnosis of a myelodysplatic syndrome with a 5q-minus deletion (del5q), type 5q-minus syndrome (5q-Syn). Our laboratory tests revealed severe anaemia (haemoglobin 5 g/dL) as well as leucopenia [2.8×10 9 /L (normal range, 3.7-9.6×10 9 /L)], while overall neutrophil and thrombocyte counts were in the normal ranges. Given the symptomatic anaemia, erythrocyte concentrate transfusions were initiated. In May 2006, we started oral therapy with lenalidomide (10 mg/day for 21 days; 28-day cycle). Already by mid-July 2006, the patient had reached a haemoglobin value of 12 g/dL (Fig. 1) This is-to our knowledge-the first long-term follow-up of a patient with a 5q-Syn having achieved haematological and borderline cytogenetic remission under lenalidomide, who then ceased therapy. In few other cases published, lenalidomide was stopped because of drug intolerance and before the patients achieved haematological remission [2] . In our case, lenalidomide was paused because of beginning polyglobulia-a well-known adverse effect of lenalidomide [3] . Furthermore, the current expert recommendations to continue treatment after achieving haematological remission [4] did not exist yet.
The therapeutic mechanism of action of lenalidomide is matter of speculation. It has been suggested that lenalidomide exerts a del5q cytotoxic effect [1, 5] and an immunomodulating effect, which could have a positive effect on bone marrow microenvironment and therefore on haematopoiesis [2, 6] . Accounting for these possible mechanisms of action, the direct cytotoxic effect of lenalidomide gives us an explanation for the rapid reappearance of del5q clone. Treatment discontinuation with achievement of borderline cytogenetic remission appears to be too short for long-term suppression of the del5q clone, probably because of the incomplete elimination of CD34 del5q-progenitor cells, insofar as complete elimination is possible [7] . However, it is noteworthy that our patient has not suffered haematological relapse for more than 26 months since discontinuing treatment, despite the rapid reappearance of the 5q-minus clone. We believe that the microenvironmental effect of lenalidomide may prolong the time interval between cytogenetic and haematologic relapse in 5q-Syn, at least for some patients. This phenomenon would be an argument against a continuous lenalidomide therapy, which is associated with possible adverse effects and enormous costs. Hb  Haemoglobin  del5q 5q-minus deletion 5q-Syn 5q-minus syndrome Hemoglobin (g/dL) Lenalidomide Neutrophils (x10e9/L) Fig. 1 Complete haematological remission was still evident 26 months after lenalidomide discontinuation
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